Loading clinical trials...
Loading clinical trials...
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of the Safety and Immunogenicity of AdCOVID Administered as One or Two Doses
Conditions
Interventions
AdCOVID
Placebo
Locations
6
United States
AGA Clinical Trials
Hialeah, Florida, United States
Optimal Research
Melbourne, Florida, United States
Optimal Research
Peoria, Illinois, United States
Optimal Research
Rockville, Maryland, United States
Optimal Research
Austin, Texas, United States
Clinical Trials of Texas
San Antonio, Texas, United States
Start Date
February 25, 2021
Primary Completion Date
December 1, 2021
Completion Date
December 21, 2022
Last Updated
August 14, 2023
NCT00104325
NCT01399385
NCT05774834
NCT07310264
NCT06904807
NCT06342713
Lead Sponsor
Altimmune, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions